1. Scrip
  2. >>R&D

Phase III Endpoint Hit For Novartis's Gilenya Follow-On In Progressive MS

 
• By Lucie Ellis-Taitt

Novartis AG's Gilenya follow-on drug, BAF312 (siponimod), has met its primary endpoint in the Phase III EXPAND trial, giving the drug a positive outlook for approval as a treatment for underserved secondary progressive multiple sclerosis (SPMS) patients.

Novartis AG announced on Aug. 25 that Gilenya (fingolimod) follow-on drug, BAF312 (siponimod), met the primary endpoint of the Phase III EXPAND trial in secondary progressive multiple sclerosis (SPMS) patients – a win for the company considering recent failures in the SPMS space.

Datamonitor Healthcare analyst Ines Guerra noted that while it is difficult to make predictions for BAF312's future on the market...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

AI Is Inevitable, But Useful Only If Solves The Right Problems

 
• By Mandy Jackson

Scrip spoke with executives at artificial intelligence biotech firms and a big pharma company during the recent BIO conference about using AI in ways that add real value to drug development.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.